CyteK Biosciences Q2 EPS USD -0.09

Cytek Biosciences, Inc. (Nasdaq: CTKB) reported second-quarter 2026 earnings per share (EPS) of -$0.09, reflecting a net loss for the period. The results were released ahead of scheduled earnings call and investor update on August 5, 2026. This follows the company’s first-quarter 2026 financial report, which showed net income of $6.3 million, or $0.05 per share.

For the second quarter of 2026, the company has not yet disclosed full financial figures, but the reported EPS indicates a decline from the positive net income in the prior quarter. The loss may be attributed to increased operating expenses or a slowdown in revenue growth, though specific details remain pending the full earnings release.

In 2025, Cytek reported a net loss of $11.3 million for the full year, with net income in the fourth quarter. The company has historically faced fluctuations in profitability, particularly due to high research and development costs and strategic investments such as acquisition of product lines from Luminex in early 2023.

Looking ahead, Cytek has outlined a 2026 revenue outlook of $203 million to $213 million, representing growth of 5% to 10% compared to 2025. The company also plans to continue investing in innovation, as evidenced by its recent announcement of next-generation spectral flow cytometry advancements at the CYTO 2026 conference.

Investors will be closely watching the full Q2 2026 earnings report for insights into the company’s operational performance and progress toward long-term profitability.